1	Three	CD	4	num
2	leading	VBG	4	amod
3	drug	NN	4	nn
4	companies	NNS	5	nsubj
5	reported	VBD	0	root
6	robust	JJ	8	amod
7	third-quarter	NN	8	nn
8	earnings	NNS	5	dobj
9	,	,	8	punct
10	bolstered	VBN	8	partmod
11	by	IN	10	prep
12	strong	JJ	13	amod
13	sales	NNS	11	pobj
14	of	IN	13	prep
15	newer	JJR	19	amod
16	,	,	19	punct
17	big-selling	JJ	19	amod
18	prescriptions	NNS	19	nn
19	drugs	NNS	14	pobj
20	that	WDT	21	nsubj
21	provide	VBP	19	rcmod
22	hefty	JJ	24	amod
23	profit	NN	24	nn
24	margins	NNS	21	dobj
25	.	.	5	punct

1	Merck	NNP	4	nsubj
2	&	CC	1	cc
3	Co.	NNP	1	conj
4	reported	VBD	0	root
5	a	DT	8	det
6	25	CD	7	number
7	%	NN	8	amod
8	increase	NN	4	dobj
9	in	IN	8	prep
10	earnings	NNS	9	pobj
11	;	:	4	punct
12	Warner-Lambert	NNP	13	nn
13	Co.	NNP	15	poss
14	's	POS	13	possessive
15	profit	NN	16	nsubj
16	rose	VBD	4	parataxis
17	22	CD	18	num
18	%	NN	16	dobj
19	and	CC	16	cc
20	Eli	NNP	21	nn
21	Lilly	NNP	26	poss
22	&	CC	21	cc
23	Co.	NNP	21	conj
24	's	POS	21	possessive
25	net	JJ	26	amod
26	income	NN	27	nsubj
27	rose	VBD	16	conj
28	24	CD	29	num
29	%	NN	27	dobj
30	.	.	4	punct

1	The	DT	2	det
2	results	NNS	3	nsubj
3	were	VBD	0	root
4	in	IN	3	prep
5	line	NN	4	pobj
6	with	IN	5	prep
7	analysts	NNS	9	poss
8	'	POS	7	possessive
9	expectations	NNS	6	pobj
10	.	.	3	punct

1	Merck	NNP	0	root
2	&	CC	1	cc
3	Co	NNP	1	conj
4	.	.	1	punct

1	Merck	NNP	7	nsubj
2	,	,	1	punct
3	Rahway	NNP	1	appos
4	,	,	3	punct
5	N.J.	NNP	3	appos
6	,	,	1	punct
7	continued	VBD	0	root
8	to	TO	9	aux
9	lead	VB	7	xcomp
10	the	DT	11	det
11	industry	NN	9	dobj
12	with	IN	9	prep
13	a	DT	16	det
14	strong	JJ	16	amod
15	sales	NNS	16	nn
16	performance	NN	12	pobj
17	in	IN	16	prep
18	the	DT	23	det
19	human	NN	22	nn
20	and	CC	19	cc
21	animal	NN	19	conj
22	health-products	NNS	23	nn
23	segment	NN	17	pobj
24	.	.	7	punct

1	A	DT	4	det
2	stronger	JJR	4	amod
3	U.S.	NNP	4	nn
4	dollar	NN	5	nsubj
5	reduced	VBD	0	root
6	third-quarter	NN	10	amod
7	and	CC	6	cc
8	first-nine-month	JJ	6	conj
9	sales	NNS	10	nn
10	growth	NN	5	iobj
11	2	CD	15	number
12	%	NN	15	dep
13	and	CC	15	cc
14	3	CD	15	conj
15	%	NN	5	dobj
16	,	,	15	punct
17	respectively	RB	15	advmod
18	.	.	5	punct

1	International	JJ	2	amod
2	sales	NNS	3	nsubj
3	accounted	VBD	0	root
4	for	IN	3	prep
5	47	CD	6	num
6	%	NN	4	pobj
7	of	IN	6	prep
8	total	JJ	10	amod
9	company	NN	10	nn
10	sales	NNS	7	pobj
11	for	IN	10	prep
12	the	DT	14	det
13	nine	CD	14	num
14	months	NNS	11	pobj
15	,	,	3	punct
16	compared	VBN	3	prep
17	with	IN	16	pcomp
18	50	CD	19	num
19	%	NN	17	pobj
20	a	DT	21	det
21	year	NN	22	npadvmod
22	earlier	RBR	17	advmod
23	.	.	3	punct

1	Sales	NNS	5	nsubj
2	for	IN	1	prep
3	the	DT	4	det
4	quarter	NN	2	pobj
5	rose	VBD	0	root
6	to	TO	5	prep
7	$	$	6	pobj
8	1.63	CD	7	number
9	billion	CD	7	number
10	from	IN	5	prep
11	$	$	10	pobj
12	1.47	CD	11	number
13	billion	CD	11	number
14	.	.	5	punct

1	Mevacor	NNP	9	nsubj
2	,	,	1	punct
3	Merck	NNP	7	poss
4	's	POS	3	possessive
5	new	JJ	7	amod
6	cholesterol-lowering	JJ	7	amod
7	drug	NN	1	appos
8	,	,	1	punct
9	had	VBD	31	ccomp
10	higher	JJR	11	amod
11	sales	NNS	9	dobj
12	than	IN	19	mark
13	any	DT	16	det
14	other	JJ	16	amod
15	prescription	NN	16	nn
16	medicine	NN	19	nsubj
17	has	VBZ	19	aux
18	ever	RB	19	advmod
19	achieved	VBN	11	dep
20	in	IN	19	prep
21	the	DT	22	det
22	U.S.	NNP	20	pobj
23	in	IN	19	prep
24	the	DT	25	det
25	year	NN	23	pobj
26	following	VBG	25	prep
27	introduction	NN	26	pobj
28	,	,	31	punct
29	the	DT	30	det
30	company	NN	31	nsubj
31	said	VBD	0	root
32	.	.	31	punct

1	The	DT	2	det
2	drug	NN	4	nsubjpass
3	was	VBD	4	auxpass
4	introduced	VBN	0	root
5	in	IN	4	prep
6	West	NNP	7	nn
7	Germany	NNP	5	pobj
8	this	DT	9	det
9	year	NN	4	tmod
10	.	.	4	punct

1	Intense	JJ	2	amod
2	competition	NN	6	nsubj
3	,	,	6	punct
4	however	RB	6	advmod
5	,	,	6	punct
6	led	VBD	0	root
7	to	TO	6	prep
8	unit	NN	9	nn
9	sales	NNS	10	nn
10	declines	NNS	7	pobj
11	for	IN	10	prep
12	a	DT	13	det
13	group	NN	11	pobj
14	of	IN	13	prep
15	Merck	NNP	21	poss
16	's	POS	15	possessive
17	established	VBN	21	amod
18	human	NN	21	nn
19	and	CC	18	cc
20	animal-health	NN	18	conj
21	products	NNS	14	pobj
22	,	,	13	punct
23	including	VBG	13	prep
24	Aldomet	NNP	23	pobj
25	and	CC	24	cc
26	Indocin	NNP	24	conj
27	.	.	6	punct

1	In	IN	12	prep
2	New	NNP	3	nn
3	York	NNP	5	nn
4	Stock	NNP	5	nn
5	Exchange	NNP	7	nn
6	composite	JJ	7	amod
7	trading	NN	1	pobj
8	yesterday	NN	12	tmod
9	,	,	12	punct
10	Merck	NN	11	nn
11	shares	NNS	12	nsubj
12	closed	VBD	0	root
13	at	IN	12	prep
14	$	$	13	pobj
15	75.25	CD	14	num
16	,	,	12	punct
17	up	IN	12	advmod
18	50	CD	19	num
19	cents	NNS	17	pobj
20	.	.	12	punct

1	Warner-Lambert	NNP	2	nn
2	Co	NNP	0	root
3	.	.	2	punct

1	Warner-Lambert	NNP	8	nsubj
2	,	,	1	punct
3	Morris	NNP	4	nn
4	Plains	NNP	1	appos
5	,	,	4	punct
6	N.J.	NNP	4	appos
7	,	,	4	punct
8	reported	VBD	0	root
9	sales	NNS	8	dobj
10	that	WDT	13	nsubj
11	were	VBD	13	cop
12	a	DT	13	det
13	record	NN	9	rcmod
14	for	IN	13	prep
15	any	DT	16	det
16	quarter	NN	14	pobj
17	and	CC	13	cc
18	the	DT	20	det
19	eighth	JJ	20	amod
20	quarter	NN	13	conj
21	in	IN	20	prep
22	a	DT	23	det
23	row	NN	21	pobj
24	of	IN	20	prep
25	20	CD	26	number
26	%	NN	31	num
27	or	CC	26	cc
28	more	JJR	26	conj
29	per-share	JJ	31	amod
30	earnings	NNS	31	nn
31	growth	NN	24	pobj
32	.	.	8	punct

1	Spurred	VBN	15	partmod
2	by	IN	1	prep
3	growth	NN	2	pobj
4	in	IN	3	prep
5	world-wide	JJ	6	amod
6	sales	NNS	4	pobj
7	of	IN	6	prep
8	the	DT	9	det
9	company	NN	12	poss
10	's	POS	9	possessive
11	prescription	NN	12	nn
12	drugs	NNS	7	pobj
13	,	,	15	punct
14	Warner-Lambert	NNP	15	nsubj
15	said	VBD	0	root
16	1989	CD	21	nsubj
17	will	MD	21	aux
18	be	VB	21	cop
19	the	DT	21	det
20	best	JJS	21	amod
21	year	NN	15	ccomp
22	in	IN	21	prep
23	its	PRP$	24	poss
24	history	NN	22	pobj
25	,	,	21	punct
26	with	IN	29	mark
27	per-share	JJ	28	amod
28	earnings	NNS	29	nsubj
29	expected	VBN	21	advcl
30	to	TO	31	aux
31	increase	VB	29	xcomp
32	more	JJR	33	mwe
33	than	IN	34	quantmod
34	20	CD	35	num
35	%	NN	31	dobj
36	to	TO	31	prep
37	about	IN	38	quantmod
38	$	$	36	pobj
39	6.10	CD	38	number
40	.	.	15	punct

1	Sales	NNS	5	nsubj
2	for	IN	1	prep
3	the	DT	4	det
4	quarter	NN	2	pobj
5	rose	VBD	0	root
6	to	TO	5	prep
7	$	$	6	pobj
8	1.11	CD	7	number
9	billion	CD	7	number
10	from	IN	5	prep
11	$	$	10	pobj
12	1.03	CD	11	number
13	billion	CD	11	number
14	.	.	5	punct

1	Prescription-drug	NN	3	nn
2	world-wide	JJ	3	amod
3	sales	NNS	4	nsubj
4	rose	VBD	0	root
5	9	CD	6	num
6	%	NN	4	dobj
7	in	IN	4	prep
8	the	DT	9	det
9	quarter	NN	7	pobj
10	to	TO	4	prep
11	$	$	10	pobj
12	340	CD	11	number
13	million	CD	11	number
14	;	:	4	punct
15	U.S.	NNP	16	nn
16	sales	NNS	17	nsubj
17	rose	VBD	4	parataxis
18	15	CD	19	num
19	%	NN	17	dobj
20	.	.	4	punct

1	The	DT	2	det
2	segment	NN	4	poss
3	's	POS	2	possessive
4	growth	NN	6	nsubjpass
5	was	VBD	6	auxpass
6	led	VBN	0	root
7	by	IN	6	prep
8	sales	NNS	7	pobj
9	of	IN	8	prep
10	the	DT	12	det
11	cardiovascular	JJ	12	amod
12	drugs	NNS	9	pobj
13	Lopid	NNP	12	dep
14	,	,	13	punct
15	a	DT	17	det
16	lipid	NN	17	nn
17	regulator	NN	13	appos
18	,	,	13	punct
19	and	CC	13	cc
20	Dilzem	NNP	13	conj
21	,	,	20	punct
22	a	DT	25	det
23	calcium	NN	24	nn
24	channel	NN	25	nn
25	blocker	NN	20	appos
26	.	.	6	punct

1	World-wide	JJ	2	amod
2	sales	NNS	24	nsubj
3	of	IN	2	prep
4	Warner-Lambert	NNP	8	poss
5	's	POS	4	possessive
6	non-prescription	JJ	8	amod
7	health-care	NN	8	nn
8	products	NNS	3	pobj
9	,	,	8	punct
10	such	JJ	11	mwe
11	as	IN	8	prep
12	Halls	NNP	14	nn
13	cough	NN	14	nn
14	tablets	NNS	11	pobj
15	,	,	14	punct
16	Rolaids	NNP	17	nn
17	antacid	NN	14	conj
18	,	,	14	punct
19	and	CC	14	cc
20	Lubriderm	NNP	22	nn
21	skin	NN	22	nn
22	lotion	NN	14	conj
23	,	,	8	punct
24	increased	VBD	0	root
25	3	CD	26	num
26	%	NN	24	dobj
27	to	TO	24	prep
28	$	$	27	pobj
29	362	CD	28	number
30	million	CD	28	number
31	in	IN	24	prep
32	the	DT	34	det
33	third	JJ	34	amod
34	quarter	NN	31	pobj
35	;	:	24	punct
36	U.S.	NNP	37	nn
37	sales	NNS	38	nsubj
38	rose	VBD	24	parataxis
39	5	CD	40	num
40	%	NN	38	dobj
41	.	.	24	punct

1	Confectionery	JJ	2	amod
2	products	NNS	3	nn
3	sales	NNS	5	nsubj
4	also	RB	5	advmod
5	had	VBD	0	root
6	strong	JJ	7	amod
7	growth	NN	5	dobj
8	in	IN	5	prep
9	the	DT	10	det
10	quarter	NN	8	pobj
11	.	.	5	punct

1	World-wide	JJ	2	amod
2	sales	NNS	18	nsubj
3	of	IN	2	prep
4	Trident	NNP	5	nn
5	gum	NN	3	pobj
6	,	,	5	punct
7	Certs	NNP	9	nn
8	breath	NN	9	nn
9	mints	NNS	5	conj
10	,	,	5	punct
11	and	CC	5	cc
12	Clorets	NNP	13	dep
13	gum	NN	5	conj
14	and	CC	13	cc
15	breath	NN	16	nn
16	mints	NNS	13	conj
17	,	,	5	punct
18	increased	VB	0	root
19	12	CD	20	num
20	%	NN	18	dobj
21	to	TO	18	prep
22	$	$	21	pobj
23	277	CD	22	number
24	million	CD	22	number
25	.	.	18	punct

1	Warner-Lambert	NNP	2	nn
2	shares	NNS	3	nsubj
3	closed	VBD	0	root
4	at	IN	3	prep
5	$	$	4	pobj
6	109.50	CD	5	num
7	a	DT	8	det
8	share	NN	5	npadvmod
9	,	,	3	punct
10	up	IN	3	advmod
11	$	$	10	pobj
12	1.50	CD	11	num
13	,	,	3	punct
14	in	IN	3	prep
15	Big	NNP	16	nn
16	Board	NNP	18	nn
17	composite	JJ	18	amod
18	trading	NN	14	pobj
19	yesterday	NN	3	tmod
20	.	.	3	punct

1	Eli	NNP	2	nn
2	Lilly	NNP	0	root
3	&	CC	2	cc
4	Co	NNP	2	conj
5	.	.	4	punct

1	Lilly	NNP	2	nsubj
2	attributed	VBD	0	root
3	record	NN	7	nn
4	third-quarter	JJ	7	amod
5	and	CC	4	cc
6	nine-month	JJ	4	conj
7	results	NNS	2	dobj
8	to	TO	2	prep
9	world-wide	JJ	10	amod
10	gains	NNS	8	pobj
11	for	IN	10	prep
12	pharmaceuticals	NNS	11	pobj
13	,	,	12	punct
14	medical	JJ	15	amod
15	instruments	NNS	12	conj
16	and	CC	12	cc
17	plant-science	NN	18	nn
18	products	NNS	12	conj
19	despite	IN	10	prep
20	poor	JJ	22	amod
21	exchange	NN	22	nn
22	rates	NNS	19	pobj
23	for	IN	22	prep
24	the	DT	25	det
25	dollar	NN	23	pobj
26	that	WDT	27	nsubj
27	slowed	VBD	22	rcmod
28	sales	NNS	27	dobj
29	abroad	RB	28	advmod
30	.	.	2	punct

1	Earnings	NNS	2	nsubj
2	continued	VBD	0	root
3	to	TO	4	aux
4	pace	VB	2	xcomp
5	sales	NNS	4	dobj
6	because	IN	7	mwe
7	of	IN	2	prep
8	a	DT	11	det
9	lower	JJR	11	amod
10	tax	NN	11	nn
11	rate	NN	7	pobj
12	,	,	11	punct
13	profit	NN	11	conj
14	from	IN	13	prep
15	the	DT	16	det
16	renegotiation	NN	14	pobj
17	of	IN	16	prep
18	the	DT	20	det
19	debt	NN	20	nn
20	instrument	NN	17	pobj
21	received	VBN	20	partmod
22	from	IN	21	prep
23	Faberge	NNP	24	nn
24	Inc.	NNP	22	pobj
25	in	IN	21	prep
26	connection	NN	25	pobj
27	with	IN	26	prep
28	Lilly	NNP	30	poss
29	's	POS	28	possessive
30	sale	NN	27	pobj
31	of	IN	30	prep
32	Elizabeth	NNP	33	nn
33	Arden	NNP	34	nn
34	Inc.	NNP	31	pobj
35	in	IN	30	prep
36	1987	CD	35	pobj
37	,	,	11	punct
38	and	CC	11	cc
39	net	JJ	40	amod
40	proceeds	NNS	11	conj
41	from	IN	40	prep
42	the	DT	43	det
43	settlement	NN	41	pobj
44	of	IN	43	prep
45	patent	NN	46	nn
46	litigation	NN	44	pobj
47	at	IN	43	prep
48	Lilly	NNP	52	poss
49	's	POS	48	possessive
50	Hybritech	NNP	51	nn
51	Inc.	NNP	52	nn
52	unit	NN	47	pobj
53	.	.	2	punct

1	Third-quarter	NN	2	nn
2	sales	NNS	10	nsubj
3	of	IN	2	prep
4	the	DT	9	det
5	Indianapolis	NNP	9	dep
6	,	,	5	punct
7	Ind.	NNP	5	dep
8	,	,	5	punct
9	company	NN	3	pobj
10	rose	VBD	0	root
11	11	CD	12	num
12	%	NN	10	dobj
13	to	TO	10	prep
14	$	$	13	pobj
15	1.045	CD	14	number
16	billion	CD	14	number
17	from	IN	10	prep
18	$	$	17	pobj
19	940.6	CD	18	number
20	million	CD	18	number
21	.	.	10	punct

1	Nine-month	JJ	2	amod
2	sales	NNS	3	nsubj
3	grew	VBD	0	root
4	12	CD	5	num
5	%	NN	3	dobj
6	to	TO	3	prep
7	$	$	6	pobj
8	3.39	CD	7	number
9	billion	CD	7	number
10	from	IN	3	prep
11	$	$	10	pobj
12	3.03	CD	11	number
13	billion	CD	11	number
14	a	DT	15	det
15	year	NN	16	npadvmod
16	earlier	RBR	10	advmod
17	.	.	3	punct

1	Sales	NNS	8	nsubj
2	of	IN	1	prep
3	Prozac	NNP	2	pobj
4	,	,	3	punct
5	an	DT	6	det
6	anti-depressant	NN	3	appos
7	,	,	3	punct
8	led	VBD	0	root
9	drug-sales	NNS	10	nn
10	increases	NNS	8	dobj
11	.	.	8	punct

1	Higher	JJR	2	amod
2	sales	NNS	11	nsubj
3	of	IN	2	prep
4	pesticides	NNS	3	pobj
5	and	CC	4	cc
6	other	JJ	8	amod
7	plant-science	NN	8	nn
8	products	NNS	4	conj
9	more	RBR	10	advmod
10	than	IN	11	advmod
11	offset	VBP	32	ccomp
12	a	DT	14	det
13	slight	JJ	14	amod
14	decline	NN	11	dobj
15	in	IN	14	prep
16	the	DT	17	det
17	sales	NNS	15	pobj
18	of	IN	17	prep
19	animal-health	NN	20	nn
20	products	NNS	18	pobj
21	to	TO	22	aux
22	fuel	VB	11	xcomp
23	the	DT	24	det
24	increase	NN	22	dobj
25	in	IN	24	prep
26	world-wide	JJ	29	amod
27	agricultural	JJ	28	amod
28	product	NN	29	nn
29	sales	NNS	25	pobj
30	,	,	32	punct
31	Lilly	NNP	32	nsubj
32	said	VBD	0	root
33	.	.	32	punct

1	Advanced	NNP	3	nn
2	Cardiovascular	NNP	3	nn
3	Systems	NNPS	4	nn
4	Inc.	NNP	10	nsubj
5	and	CC	4	cc
6	Cardiac	NNP	7	nn
7	Pacemakers	NNPS	8	nn
8	Inc.	NNP	9	nn
9	units	NNS	4	conj
10	led	VBD	0	root
11	growth	NN	10	dobj
12	in	IN	11	prep
13	the	DT	16	det
14	medical-instrument	JJ	15	amod
15	systems	NNS	16	nn
16	division	NN	12	pobj
17	.	.	10	punct

1	Lilly	NNP	2	nn
2	shares	NNS	3	nsubj
3	closed	VBD	0	root
4	yesterday	NN	3	tmod
5	in	IN	3	prep
6	composite	JJ	7	amod
7	trading	NN	5	pobj
8	on	IN	7	prep
9	the	DT	11	det
10	Big	NNP	11	nn
11	Board	NNP	8	pobj
12	at	IN	3	prep
13	$	$	12	pobj
14	62.25	CD	13	num
15	,	,	3	punct
16	down	IN	3	advmod
17	12.5	CD	18	num
18	cents	NNS	16	pobj
19	.	.	3	punct


